[
  {
    "question": "A 58-year-old woman with HIV infection is brought to the emergency department because of a 2-week history of headaches, blurred vision, and confusion. Her current medications include antiretroviral therapy and trimethoprim-sulfamethoxazole. Neurological examination shows ataxia and memory impairment. Her CD4+ T-lymphocyte count is 90/\u03bcL. Analysis of her cerebrospinal fluid analysis shows lymphocytic predominant pleocytosis, and PCR is positive for Epstein-Barr virus DNA. An MRI of the brain with contrast shows a solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum. What is the most likely diagnosis?",
    "answer": "Given the clinical picture \u2013 HIV infection with low CD4, neurological symptoms (headache, blurred vision, confusion, ataxia, memory impairment), CSF findings (lymphocytic pleocytosis, EBV positivity), and MRI findings (solitary, ring-enhancing lesion in the corpus callosum) \u2013 the most likely diagnosis is **Progressive Multifocal Leukoencephalopathy (PML)**.\n\nHere's why:\n\n*   **Immunocompromised state:** CD4 count of 90/\u03bcL indicates significant immunosuppression.\n*   **EBV association:** EBV is often reactivated in PML, though it doesn't *cause* it. It's a marker of immunosuppression.\n*   **MRI findings:** A solitary, ring-enhancing lesion in the corpus callosum is classic for PML.\n*   **Neurological symptoms:** The symptoms align with the areas of brain affected by PML.\n\nWhile other possibilities exist (like toxoplasmosis), PML is the most probable given the constellation of findings.",
    "true_answer": "The most likely diagnosis for a patient with HIV, presenting with neurological symptoms and a solitary ring-enhancing lesion, is primary cerebral lymphoma."
  },
  {
    "question": "A 25-year-old sexually active male presents to an internal medicine physician for a routine health check up after having several unprotected sexual encounters. After appropriate testing the physician discusses with the patient that he is HIV+ and must be started on anti-retroviral treatment. What medication prescribed acts on the gp41 subunit of the HIV envelope glycoprotein?",
    "answer": "That's a good question for a new clinician to ask!\n\n**Enfuvirtide** is the antiretroviral medication that acts on the gp41 subunit of the HIV envelope glycoprotein. It's a fusion inhibitor.\n\nHowever, it's not typically a first-line agent due to its administration route (subcutaneous injection) and tolerability issues. Current guidelines favor starting with integrase inhibitors, or other agents with fewer side effects and simpler dosing.",
    "true_answer": "The medication that targets the gp41 subunit of the HIV envelope glycoprotein is enfuvirtide."
  },
  {
    "question": "A 27-year-old man presents with a 2-week history of fever, malaise, and occasional diarrhea. On physical examination, the physician notes enlarged inguinal lymph nodes. An HIV-1 detection test is positive. Laboratory studies show a CD4+ count of 650/mm3. This patient is most likely currently in what stage of HIV infection?",
    "answer": "Acute HIV infection. \n\nA recent positive HIV test with these symptoms, *and* a relatively normal CD4 count, strongly suggests the patient is in the acute seroconversion phase. The CD4 count hasn't yet been significantly impacted.",
    "true_answer": "This patient is most likely currently in the stage of acute HIV infection."
  },
  {
    "question": "A 50-year-old male with HIV presents to his primary care provider complaining of persistent fevers and night sweats over the past four months. He has also experienced a productive cough. He has been poorly adherent to his HAART regimen. His past medical history also includes gout, hypertension, and diabetes mellitus. He takes allopurinol, enalapril, and metformin. His temperature is 100.9\u00b0F (38.3\u00b0C), blood pressure is 125/75 mmHg, pulse is 95/min, and respirations are 20/min. His CD4 count is 85 cell/mm^3 and a PPD is negative. A chest radiograph reveals cavitations in the left upper lobe and left lower lobe. Bronchoalveolar lavage reveals the presence of partially acid-fast gram-positive branching rods. A head CT is negative for any intracranial process. What is the mechanism of action of the most appropriate drug for managing this patient\u2019s condition?",
    "answer": "Given the clinical picture \u2013 fever, night sweats, cough, low CD4, cavitary lesions on chest X-ray, and the presence of partially acid-fast gram-positive branching rods in the BAL \u2013 this patient most likely has *Nocardia* pneumonia.\n\nThe most appropriate drug is typically **trimethoprim-sulfamethoxazole (TMP-SMX)**. \n\nIts mechanism of action involves sequentially blocking two steps in the folic acid synthesis pathway in *Nocardia*. Specifically, **trimethoprim inhibits dihydrofolate reductase, while sulfamethoxazole inhibits dihydropteroate synthase.** This combined blockade prevents the organism from producing tetrahydrofolic acid, which is essential for DNA and RNA synthesis, ultimately inhibiting bacterial growth.",
    "true_answer": "The mechanism of action of the most appropriate drug to manage this patient's condition is inhibition of bacterial folic acid synthesis."
  },
  {
    "question": "A physician scientist is looking for a more efficient way to treat HIV. Patients infected with HIV mount a humoral immune response by producing antibodies against the HIV envelope proteins. These antibodies are the same antibodies detected by the ELISA and western blot assays used to diagnose the disease. The physician scientist is trying to generate a new, more potent antibody against the same HIV envelope proteins targeted by the natural humoral immune response. Of the following proteins, which is the most likely target of the antibody he is designing?",
    "answer": "That's a good research direction. To answer your question, the most likely target is **gp120**. \n\nHere's why:\n\n*   **gp120** is the external glycoprotein of the HIV envelope, and the primary target of neutralizing antibodies. It's crucial for initial viral entry into cells. A potent antibody here could block infection.\n*   While the envelope also contains **gp41**, it's more involved in membrane fusion *after* gp120 binds to the cell. Blocking gp120 prevents the whole process.\n*   The other options (reverse transcriptase, integrase, protease) are internal viral enzymes - antibodies generally don't have good access to these once the virus is inside the cell.\n\nEssentially, you want to disrupt the virus *before* it enters the cell, and gp120 is the most accessible and crucial target for that.",
    "true_answer": "The most likely target of the antibody being designed for HIV envelope proteins is gp120."
  },
  {
    "question": "A 50-year-old HIV-positive male presents to the ER with a two-day history of fever and hemoptysis. Chest radiograph shows a fibrocavitary lesion in the right middle lobe. Biopsy of the afflicted area demonstrates septate hyphae that branch at acute angles. What is the most likely causal organism?",
    "answer": "That clinical picture strongly suggests *Aspergillus* species. The combination of fever, hemoptysis, fibrocavitary lesion in an immunocompromised host (HIV-positive), and acute-angle branching septate hyphae on biopsy is highly characteristic of invasive aspergillosis.",
    "true_answer": "The most likely causal organism for the symptoms presented is Aspergillus fumigatus."
  },
  {
    "question": "A 43-year-old man with HIV infection comes to the physician because of a 2-week history of progressive diarrhea and a 3-kg (6.6-lb) weight loss. During this period, he has had 3\u20134 episodes of watery stools daily, with multiple instances of blood in the stool. He is currently receiving antiretroviral therapy with zidovudine, lamivudine, and dolutegravir. Physical examination shows pallor and dry mucous membranes. A colonoscopy shows multiple linear ulcers. Polymerase chain reaction of a stool sample is positive for cytomegalovirus. Treatment with valganciclovir is begun. Adding this drug to his current medication regimen puts this patient at greatest risk for what specific adverse effects?",
    "answer": "Valganciclovir, combined with zidovudine, carries a significant risk of **myelosuppression** \u2013 specifically, neutropenia and anemia. Both drugs can independently cause bone marrow suppression, and the combination increases this risk substantially.",
    "true_answer": "Treatment with valganciclovir places the patient at increased risk for pancytopenia."
  },
  {
    "question": "A 28-year-old G1P0 woman at 16 weeks estimated gestational age presents for prenatal care. Routine prenatal screening tests are performed and reveal a positive HIV antibody test. The patient is extremely concerned about the possible transmission of HIV to her baby and wants to have the baby tested as soon as possible after delivery. Which of the following would be the most appropriate diagnostic test to address this patient\u2019s concern?",
    "answer": "That's a very common and understandable concern. The most appropriate test immediately after delivery isn't a standard HIV antibody test \u2013 that will reflect *her* antibodies, not necessarily if the baby is infected. \n\nYou'd want to order **HIV-1 NAT (nucleic acid testing)**, specifically a PCR test, on the infant. This detects the virus itself. It\u2019s most accurate after 24-48 hours of life, but can be done earlier if clinical suspicion is high.",
    "true_answer": "The most appropriate test for early HIV diagnosis in a newborn is the polymerase chain reaction (PCR) for HIV RNA."
  },
  {
    "question": "A 32-year-old man comes to the office for a routine health maintenance examination. He admits to recently having an affair several months ago and requests STD testing. One week later, the results of a fourth-generation HIV antibody and antigen test return positive. The patient is counseled on the test result. The patient requests that his diagnosis not be disclosed to anyone, including his wife. The man's wife is also the physician's patient. What should be the most appropriate next step by the physician?",
    "answer": "This is a complex ethical and legal situation. The most appropriate next step is **focused counseling of the patient regarding the legal and ethical obligations surrounding HIV disclosure.**\n\nHere's why, and what that counseling should cover:\n\n*   **Legal Duty to Warn:** Many jurisdictions have laws regarding partner notification for reportable infectious diseases like HIV. The physician needs to explain this to the patient.\n*   **Potential Criminal Liability:** The patient needs to understand that knowingly transmitting or potentially transmitting HIV can carry criminal penalties.\n*   **Ethical Obligations:** Discuss the ethical implications of non-disclosure, particularly the risk to his wife\u2019s health.\n*   **Assisted Notification:** Offer assistance with notifying his wife, including having a public health professional do so anonymously.\n*   **Confidentiality Limits:** Clearly state that while you respect his desire for confidentiality, your primary obligation is to public health and potentially to his wife's well-being.\n\n**You cannot guarantee confidentiality if it poses a significant risk to another person.** You need to document this counseling thoroughly.\n\nIt's also wise to consult with a legal expert or ethics committee within your hospital/practice for guidance specific to your location.",
    "true_answer": "The physician should report the HIV infection to the national health authorities while maintaining confidentiality per regulations."
  },
  {
    "question": "A 41-year-old woman presents with acute onset severe epigastric pain radiating to the back that began a few hours ago. She also complains of nausea and has vomited twice in the past hour. She denies any history of similar symptoms or trauma in the past. Past medical history is significant for diabetes type 2 and HIV infection diagnosed 6 months ago long-standing mild intermittent asthma, and generalized anxiety disorder. She takes metformin for her diabetes but does not remember the names of her HIV medications. She reports moderate social alcohol use. Her vital signs include temperature 37.6\u00b0C (99.6 \u00b0F), pulse 95/min, blood pressure 110/74 mm Hg, respiratory rate 12/min Her body mass index (BMI) is 21 kg/m2. Laboratory findings are significant for the following: Serum amylase: 415 U/L, Serum lipase: 520 U/L. A contrast CT of the abdomen reveals an edematous pancreas with peripancreatic fluid collection with a normal gallbladder. What is the most likely etiology of this patient\u2019s condition?",
    "answer": "Given the clinical presentation \u2013 acute epigastric pain radiating to the back, nausea, vomiting, elevated amylase and lipase, and CT findings of pancreatitis \u2013 the most likely etiology is **acute pancreatitis**. \n\nWhile her HIV infection is part of her medical history, it's less directly linked to *acute* pancreatitis onset than other factors. Medication side effects (potentially from HIV meds, though we don't know what they are yet), alcohol use, and potentially undiagnosed gallstones (though the CT ruled that out) are more common triggers. Diabetes is also a risk factor.",
    "true_answer": "It is most likely related to their HIV medication."
  },
  {
    "question": " A 28-year-old primigravid woman at 38 weeks' gestation is brought to the emergency department in active labor. She has not had regular prenatal care. She has a history of HIV infection but is not currently on antiretroviral therapy. Her previous viral load is unknown. Treatment with intravenous zidovudine is begun to reduce perinatal transmission of the virus. What biological process is most likely disrupted by this drug\u2019s action mechanism?",
    "answer": "That's a good question to consider in this clinical scenario.\n\nZidovudine (AZT) is a nucleoside reverse transcriptase inhibitor (NRTI). Therefore, the biological process most disrupted by its action is **reverse transcription** \u2013 the process by which HIV converts its RNA genome into DNA.",
    "true_answer": " Zidovudine affects elongation of viral DNA by inhibiting the viral reverse transcriptase enzyme."
  },
  {
    "question": "What is known about DNA methylation profiles in patients with latent HIV-1 or with an active infection?",
    "answer": "That's a good question, and an area of active research. Here's a concise overview:\n\n**Latent HIV-1:** Studies show altered DNA methylation patterns in latently infected cells, particularly at the HIV-1 provirus itself. Generally, increased methylation is associated with transcriptional silencing \u2013 a key feature of latency. However, it\u2019s not a simple on/off switch; methylation patterns are complex and vary by cell type.\n\n**Active Infection:** Active HIV-1 infection also disrupts host DNA methylation. This is thought to contribute to immune dysfunction and disease progression. The changes are more global than those seen in latency, affecting many host genes involved in immune function.\n\n**Important Note:** These methylation changes are *associated* with viral status, but we don't yet fully understand if they *cause* latency or disease progression, or are simply a consequence of infection. It's likely a complex interplay.",
    "true_answer": "DNA methylation is correlated with and functionally linked to HIV-1 pathogenesis and latency. In active infection, HIV-1 infection is associated with global changes in host cell DNA methylation patterns, while in latent infection, methylation of the proviral DNA, particularly in the 5\u2019 LTR promoter and intragenic regions, plays a crucial role in maintaining viral latency."
  }
]